An association study in PTPN22 suggests that is a risk factor to Takayasu’s arteritis

Soto, Marí­a Elena; Montúfar-Robles, Isela; Jiménez-Morales, Silvia; Gamboa, Ricardo; Huesca-Gómez, Claudia; Ramírez‐Bello, Julián

doi:10.1007/s00011-018-1204-1

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, healthy individuals who harbor the autoimmunity-linked variant of PTPN22 display heightened autoreactivity within the naïve B cell repertoire, characterized by an increase in transitional and anergic B cell subsets marked by IgD + IgM − CD27 − phenotype [ 78 , 79 ]. In + TAK, the BCR signaling variant PTPN22 R620W is associated with enhanced susceptibility to TAK [ 80 ]. While not yet studied in detail, PTPN22 R620W may promote greater autoreactivity in mature cells in TAK.…”

Section: B Cell Checkpoints In Takmentioning

confidence: 99%

A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu’s Arteritis

Guo,

Tian,

et al. 2024

IJMS

View full text Add to dashboard Cite

Takayasu’s arteritis (TAK) manifests as an insidiously progressive and debilitating form of granulomatous inflammation including the aorta and its major branches. The precise etiology of TAK remains elusive, with current understanding suggesting an autoimmune origin primarily driven by T cells. Notably, a growing body of evidence bears testimony to the widespread effects of B cells on disease pathogenesis and progression. Distinct alterations in peripheral B cell subsets have been described in individuals with TAK. Advancements in technology have facilitated the identification of novel autoantibodies in TAK. Moreover, emerging data suggest that dysregulated signaling cascades downstream of B cell receptor families, including interactions with innate pattern recognition receptors such as toll-like receptors, as well as co-stimulatory molecules like CD40, CD80 and CD86, may result in the selection and proliferation of autoreactive B cell clones in TAK. Additionally, ectopic lymphoid neogenesis within the aortic wall of TAK patients exhibits functional characteristics. In recent decades, therapeutic interventions targeting B cells, notably utilizing the anti-CD20 monoclonal antibody rituximab, have demonstrated efficacy in TAK. Despite the importance of the humoral immune response, a systematic understanding of how autoreactive B cells contribute to the pathogenic process is still lacking. This review provides a comprehensive overview of the biological significance of B cell-mediated autoimmunity in TAK pathogenesis, as well as insights into therapeutic strategies targeting the humoral response. Furthermore, it examines the roles of T-helper and T follicular helper cells in humoral immunity and their potential contributions to disease mechanisms. We believe that further identification of the pathogenic role of autoimmune B cells and the underlying regulation system will lead to deeper personalized management of TAK patients. We believe that further elucidation of the pathogenic role of autoimmune B cells and the underlying regulatory mechanisms holds promise for the development of personalized approaches to managing TAK patients.

show abstract

Section: B Cell Checkpoints In Takmentioning

confidence: 99%